CorMedix
CRMDCorMedix Inc. (NASDAQ: CRMD) is a biopharmaceutical company based in the United States. Its primary business focus is the development and commercialization of therapeutic products designed for the prevention and treatment of infectious and inflammatory diseases. The company's efforts are concentrated on addressing medical needs within the hospital and acute care settings. The company's lead product candidate is DefenCath® (taurolidine, heparin lock solution). This is an investigational, non-antibiotic catheter lock solution intended to reduce catheter-related bloodstream infections in patients with kidney failure receiving chronic hemodialysis via a central venous catheter. DefenCath has received Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration. CorMedix's pipeline also includes preclinical programs targeting anti-inflammatory and anti-infective mechanisms. As a publicly traded entity, CorMedix's strategic operations are centered on advancing its clinical-stage asset through the regulatory process and establishing the necessary commercial infrastructure for a potential launch. The company’s activities are specifically targeted within the biotech and anti-infective therapeutic sectors.
CRMD · Stock Price
Historical price data
About
CorMedix Inc. (NASDAQ: CRMD) is a biopharmaceutical company based in the United States. Its primary business focus is the development and commercialization of therapeutic products designed for the prevention and treatment of infectious and inflammatory diseases. The company's efforts are concentrated on addressing medical needs within the hospital and acute care settings. The company's lead product candidate is DefenCath® (taurolidine, heparin lock solution). This is an investigational, non-antibiotic catheter lock solution intended to reduce catheter-related bloodstream infections in patients with kidney failure receiving chronic hemodialysis via a central venous catheter. DefenCath has received Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration. CorMedix's pipeline also includes preclinical programs targeting anti-inflammatory and anti-infective mechanisms. As a publicly traded entity, CorMedix's strategic operations are centered on advancing its clinical-stage asset through the regulatory process and establishing the necessary commercial infrastructure for a potential launch. The company’s activities are specifically targeted within the biotech and anti-infective therapeutic sectors.